Related Experiment Video
Updated: Aug 26, 2025
The Influence of Liver Resection on Intrahepatic Tumor Growth
Published on: April 9, 2016
Making liver cancer cells go ARGh!
Alessa L Henneberg1,2, Christiane A Opitz1,3
1Metabolic Crosstalk in Cancer, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Abstract:
A recent study by Missiaen et al (2022) uncovers hepatocellular carcinoma (HCC) cells to downregulate urea cycle enzymes and rely on the uptake of exogenous arginine and GCN2 kinase-dependent cell-cycle arrest for survival. These results offer new avenues for combinatorial targeting of liver cancer.
Insights
Hepatocellular carcinoma cells survive by downregulating urea cycle enzymes and taking up arginine. Targeting these pathways offers new strategies for liver cancer treatment.
Area of Science:
- Oncology
- Biochemistry
- Cell Biology
Background:
- Hepatocellular carcinoma (HCC) is a major global health concern.
- Understanding cancer cell metabolism is crucial for developing effective therapies.
Purpose of the Study:
- To investigate the metabolic adaptations of hepatocellular carcinoma cells.
- To identify novel therapeutic targets for liver cancer.
Main Methods:
- Analysis of urea cycle enzyme expression in HCC cells.
- Assessment of arginine uptake and utilization.
- Investigation of GCN2 kinase signaling pathways.
Main Results:
- HCC cells downregulate key urea cycle enzymes.
- These cancer cells depend on exogenous arginine for survival.
- GCN2 kinase-dependent cell-cycle arrest is essential for HCC cell viability.
Conclusions:
- Hepatocellular carcinoma cells exhibit altered metabolic dependencies.
- Targeting urea cycle enzymes and arginine uptake presents a potential combinatorial therapeutic strategy.
- Inhibition of GCN2 kinase may be beneficial in treating liver cancer.
